Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease in Complex with N-[(1R)-2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide inhibitor.

Jon Jacobs (Contributor)
Valerie Grum-Tokars (Contributor)
Ya Zhou (Contributor)
Mark Turlington (Contributor)
S. Adrian Saldanha (Contributor)
Peter Chase (Contributor)
Aimee Eggler (Contributor)
Eric S. Dawson (Contributor)
Yahira M. Baez-Santos (Contributor)
Sakshi Tomar (Contributor)
Anna M. Mielech (Contributor)
S. C. Baker (Contributor)
Craig W. Lindsley (Contributor)
Peter Hodder (Contributor)
Andrew D. Mesecar (Contributor)
Shaun R. Stauffer (Contributor)

Dataset

1 Article

1 results

Filter

2013
Discovery, synthesis, and structure-based optimization of a series of N -(tert -Butyl)-2-(N -arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease
Jacobs, J., Grum-Tokars, V., Zhou, Y., Turlington, M., Saldanha, S. A., Chase, P., Eggler, A., Dawson, E. S., Baez-Santos, Y. M., Tomar, S., Mielech, A. M., Baker, S. C., Lindsley, C. W., Hodder, P., Mesecar, A. & Stauffer, S. R., Jan 24 2013, In: Journal of Medicinal Chemistry. 56, 2, p. 534-546 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
173 Scopus citations